In a study including 668 postmenopausal patients with HR+, HER2- recurrent, or metastatic BC who were evaluated for PFS with the combination of reboxinib and letrozole, 3.6% subjects showed prolonged QT intervals (78). This evidence concerns the gene HR and breast cancer.